Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy

Journal of Clinical Investigation

Volumn 98, Issue 12, 1996, Pages 2801-2804

  Becker, Jürgen C ^a,b   Varki, Nissi ^c   Gillies, Stephen D ^d   Furukawa, Koichi ^e   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fuji ImmunoPharmaceuticals Corp   (United States)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

antibody; cytokine; fusion protein; melanoma; T cell

Indexed keywords

GANGLIOSIDE ANTIBODY; HYBRID PROTEIN; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SUPPRESSOR CELL; THYMOMA;

EID: 0030453784     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119107     Document Type: Article

References (23)

1. Maas, R.A., H.F.J. Dullens, and W.D. Otter. 1993. IL2 in cancer treatment. Cancer Immunol. Immunother. 36:141-148.
2. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, L.C. Yang, C.A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J.P. Wei, and D.E. White. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319:1676-1680.
3. Winkelhake, J.L., and S.S. Gauny. 1990. Human recombinant interleukin-2 as an experimental therapeutic. Pharm. Rev. 42:1-64.
4. Pardoll, D.M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399-415.
5. Paul, W.E., and R. A. Seder. 1994. Lymphocyte responses and cytokines. Cell. 76:241-251.
6. Dranoff, G., and R.C. Mulligan. 1995. Gene transfer as cancer treatment. Adv. Immunol. 58:417-454.
7. Zatloukal, K., A. Schneeberger, M. Berger, W. Schmidt, F. Koszik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, E. Payer, S.G. and M.L. Birnstiel. 1995. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J. Immunol. 154:3406-3419.
8. Maass, G., W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M.L. Birstiel, and T. Schweighoffer. 1995. Priming of tumor specific T cells in the draining lymph nodes after immunization with IL2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA. 92:5540-5544.
9. Becker, J.C., N.M. Varki, S.D. Gillies, K. Furukawa, and R.A. Reisfeld. 1996. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA. 93:7826-7831.
10. Becker, J.C., J.D. Pancook, S.D. Gillies, K. Furukawa, and R.A. Reisfeld. 1996. T cell mediated eradication of murine metastatic melanoma induced by targeted interleukm 2 therapy. J. Exp. Med. 183:2361-2366.
11. Gillies, S.D., E.B. Reilly, K.-M. Lo, and R.A. Reisfeld. 1992. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Nat. Acad. Sci. USA. 89:1428-1432.
12. Haraguchi, M., S. Yamashiro, A. Yamamoto, K. Furukawa, K. Takamiya, K.O. Lloyd, H. Shiku, and K. Furukawa. 1994. Isolation of GD3 synthase gene by expression cloning of GM3 α-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA. 91:10455-10459.
13. Gillies, S.D., K.-M. Lo, and J. Wesolowski. 1989. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol. Methods. 125:191-202.
14. Gillies, S.D., D. Young, K.-M. Lo, S.F. Foley, and R.A. Reisfeld. 1991. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti ganglioside GD2 antibody. Hybridoma. 3:347-356.
15. VanPel, A., and T. Boon. 1982. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. USA. 79:4718-4722.
16. Prehn, R.T., and G.L. Bartlett. 1987. surveillance, latency and the two levels of MCA-induced tumor immunogenicity. Int. J. Cancer. 39:106-110.
17. Prehn, R.T. 1980. Immunotherapy by chemotherapy. INSERM (Inst. Natl. Sante Rech. Med.) Colloq. 97:297-303.
18. Nair, S., A.M.J. Buiting, R.J.D. Rouse, N. VanRooijen, L. Huang, and B.T. Rouse. 1995. Role of macrophages and dentritic cells in primary cytotoxic T cell responses. Int. Immunol. 7:679-688.
19. Sprent, J. 1994. T and B memory cells. Cell. 76:315-322.
20. + T cells. J. Immunol. 155:1873-1883.
21. Mackay, C.R. 1991. T Cell memory: the connection between function, phenotype, and migration pathways. Immunol. Today. 12:189-193.
22. George, A.J.T., R.A. Spooner, and A.A. Epenetos. 1994. Applications of monoclonal antibodies in clinical oncology. Immunol. Today. 15:559-561.
23. Ghetie, M.-A., and E.S. Vitetta. 1994. Recent developments in immunotoxin therapy. Curr. Opin. Immunol. 6:707-714.